Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Sep 24, 2019 10:16am
229 Views
Post# 30158556

RE:RE:RRR for 3 point MACE is not lower than RRR for 5 points MACE

RE:RE:RRR for 3 point MACE is not lower than RRR for 5 points MACE"Folks, it's all acadamic at this point. This matter will be decided any day now"
 
Exactly G1945V. My post was intended to point out the objective facts not to predict success or failure of BETonMACE. The Phase 2 post-hocs are very encouraging, but do have limitations as I pointed out. How one extrapolates this information to BETonMACE is subject to bias and interpretation. There are equally good arguments for why BETonMACE should succeed as well as for uncertainty of success. The hypothesis for apabetalone eliciting benefit in BETonMACE is solid. But all hypotheses need to be tested in the gold standard randomized controlled trial. Tick tock.

BearDownAZ
Bullboard Posts